Background: Nimotuzumab is a humanized anti-epidermal growth factor receptor (EGFR) monoclonal
antibody, nowadays used for tumour immunochemotherapy. This study aimed to label the conjugate DOTA-nimotuzumab
with yttrium-90, in order to provide a β- emitting radioimmunoconjugate (90Y-DOTA-nimotuzumab) potentially useful to
assess the feasibility of a new radio-guided surgery approach.
Methods: The synthesis of 90Y-DOTA-nimotuzumab was performed in two days. Nimotuzumab was conjugated with a 50
fold excess of DOTA and then labelled with 90Y3+. The 90Y-DOTA-nimotuzumab preparation was optimized considering
several parameters such as pH, temperature and reaction volume. Moreover, the 90Y-DOTA-nimotuzumab stability was
evaluated in human plasma.
Results: The radioimmunoconjugate 90Y-DOTA-nimotuzumab was obtained with a radiochemical purity greater than
96%, and showed a good stability at 20°C as well as at 37°C in human plasma.
Conclusions: The optimized conditions for a mild and easy preparation of 90Y-DOTA-nimotuzumab joined to a promising
stability under physiological conditions suggest to propose this radioimmunoconjugate as a potential diagnostic
radiopharmaceutical for β- radio-guided surgery.